A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
Dr David Miller
Director, Translational Research and Industrial Partnerships (School of Life and Medical Sciences)
T: 020 7679 6584
David Miller joined UCL in September 2009 to take up a Drug Discovery Leader role with the remit of helping UCL in developing and implementing integrated drug discovery strategies and to provide drug discovery expertise in the development of a portfolio of therapeutic targets. Since joining, David has successfully implemented the UCL Therapeutic Innovation Fund which provides seed funding for therapeutic projects. In 2011, he became head of the Translational Research Office, which supports the translation of UCL’s basic and clinical research into therapies, techniques and medicinal products with therapeutic value. His role has recently grown to include leading on the development of industrial partnerships in the School of Life and Medical Sciences.
David originally trained as a pharmacist before completing a PhD in medicinal chemistry at Heriot-Watt and post-doctoral synthetic organic chemistry research in Cardiff and the ETH, Zuerich. David brings over 20 years’ experience of drug discovery science and management in the pharmaceutical industry, latterly as a Director of Medicinal Chemistry with GlaxoSmithKline.